Category: ibs.GRANADA

On September 21st, the course “Industrial Property: The Essentials at a Glance” was held at the Virgen de las Nieves University Hospital. It was organized by FIBAO, ibs.GRANADA, and the Spanish Patent and Trademark Office (OEPM), which reports to the Ministry of Industry and Tourism. The session was led by Ruth Bozal Callejo, Examiner of […]

Two researchers from the ibs.GRANADA Biosanitary Research Institute, Dafina Petrova and Federico García García, participated in Meet the Researcher, a science outreach initiative linked to the European Researchers' Night that offers an opportunity to get to know the people behind the research and the work they carry out. […]

More than 700 researchers will participate this Friday night in 300 activities in Granada, Ceuta, and Melilla, with a wide-ranging program aimed at the more than 5.000 expected attendees. The Granada Institute for Biomedical Research (ibs.GRANADA) is participating once again in the European Researchers' Night, one of the leading events of its kind.

A study by the Granada Institute for Biomedical Research (ibs.GRANADA) and the University of Granada reveals that detecting bacterial DNA in the endometrium does not necessarily mean that the microorganisms are active and questions whether lactobacilli form a stable community in this tissue. Knowing which microorganisms are present in the uterine cavity and determining whether […]

María José Sánchez Pérez, scientific director of the Granada Institute for Biomedical Research (ibs.GRANADA), has been appointed Director General of Research, Innovation, and Training for the Regional Government of Andalusia. This appointment marks a new stage in Dr. Sánchez's professional career, which in recent years has been linked to the management and promotion of […]

Researchers from the Granada Institute for Biomedical Research (ibs.GRANADA), the University of Granada (UGR), and the Virgen de las Nieves University Hospital have demonstrated in preclinical models that palbociclib, siramesin, and β-lapachone inhibit the growth of small cell lung cancer through complementary mechanisms, reinforcing their potential as maintenance therapies after […]

Researchers from GENyO, the University of Granada, and the Granada Institute for Biomedical Research have identified TUSC7 as a promising biomarker for lung cancer and demonstrated that one of its mutations modifies the behavior of tumor cells, reinforcing its potential for diagnosis and personalized medicine. Lung cancer continues to be a leading cause of cancer research.